Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01525368
Other study ID # cogT002
Secondary ID
Status Completed
Phase N/A
First received January 24, 2012
Last updated November 11, 2014
Start date September 2010
Est. completion date July 2014

Study information

Verified date November 2014
Source Ludwig-Maximilians - University of Munich
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Ministry of Food, Agriculture and Consumer Protection
Study type Observational

Clinical Trial Summary

Cognitive training has been shown to be successful in patients with amnestic mild cognitive impairment (aMCI), a group at high-risk for Alzheimer's disease (AD). Moreover, in a randomized controlled trial, the investigators recently found that aMCI patients receiving a cognitive intervention showed stable hypometabolism in FDG-PET, whereas patients in an active control group showed pronounced hypometabolism on follow-up scans in regions typically affected in AD.

Previous studies indicate that not all patients respond equally well to a cognitive intervention. Identifying factors that predict response to treatment could help selecting patients for a targeted intervention. A potentially important predictor is cognitive reserve defined as premorbid cognitive performance. The hypothesis is that different levels of cognitive reserve (high cognitive reserve vs. low cognitive reserve) have different neurostructural and neurofunctional correlates and influence treatment response in a different way. Moreover, the impact of white matter lesions on treatment effects will be investigated.

The investigator will perform a complex cognitive training program. Forty patients with aMCI (20 with high cognitive reserve, 20 with low cognitive reserve) will be recruited in this study. Since the patients are recruited consecutively, an estimated overall number of 80 will be included and receive the training of whom about 40 will meet the inclusion criteria for our cognitive-reserve-study (high or low cognitive reserve). Data of the whole group will be used to analyze the potential impact of white matter lesions on response to the intervention. Cognitive effects of the intervention will be evaluated by neuropsychological testing. Neurofunctional and neurostructural changes depending on cognitive reserve will be measured using resting state fMRI and diffusion tensor imaging (DTI).

For comparison, a group of 30 aMCI patients will be recruited as an active control group receiving study investigations (neuropsychological testing as well as MRIs), and exercises for self-study at home, not the complex cognitive intervention.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date July 2014
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- male or female patients, fulfilling PetersenĀ“s criteria of amnestic mild cognitive impairment (aMCI)

- No evidence for other psychiatric axis I disorders according to DSM-IV criteria.

- No evidence for neurological disorders (e.g. stroke)

- No uncontrolled arterial hypertension or diabetes mellitus

- No history of drug / alcohol abuse

- The patient is able to provide written informed consent to participate in the study.

- for the cognitive-reserve-study patients, a high (low) cognitive reserve is defined as a verbal IQ score of >/= 120 (</= 110) as assessed by the MWT-B, a German multiple vocabulary test

Exclusion Criteria:

- Evidence for acute psychiatric or neurological disorders

- Uncontrolled arterial hypertension or diabetes mellitus

- History of drug / alcohol abuse

- No ability to participate and no willing to give informed consent and comply with the study restrictions.

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Behavioral:
cognitive intervention
Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.

Locations

Country Name City State
Germany Institute for Stroke and Dementia Research, Campus Grosshadern, Ludwig-Maximilian University Munich

Sponsors (1)

Lead Sponsor Collaborator
Ludwig-Maximilians - University of Munich

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in California Verbal Learning Test month 0 and month 6 No
Primary Change in overall cognition (ADAScog) month 0 and month 6 No
Primary Change in Face-Name Learning Test month 0 and month 6 No
Secondary Change in appraisal of quality of life (SF-36) month 0 and 6 No
Secondary Change in neurofunctional MRT (resting state fMRI) month 0 and 6 No
Secondary Change in depression scores (Beck Depression Inventory) month 0 and month 6 No
Secondary Change in working memory (Digit Span) month 0 and month 6 No
Secondary Change in attention (Trail Making Test) month 0 and month 6 No
Secondary Change in executive functions (Stroop Test) month 0 and month 6 No
Secondary Change in neurostructural MRI (diffusion tensor imaging) month 0 and month 6 No
See also
  Status Clinical Trial Phase
Completed NCT00785759 - Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers Phase 2
Recruiting NCT05903573 - Training Response Artificial Intelligence Network (TRAIN) N/A
Completed NCT02562989 - [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001) Phase 1
Completed NCT02910739 - An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016) Phase 1
Not yet recruiting NCT04103463 - Interactive Stepping Exercise on Memory N/A
Completed NCT04185298 - mSIM: Mobile Simultaneous Aerobic Exercise and Memory Training Intervention for Amnestic Mild Cognitive Impairment N/A
Recruiting NCT04063956 - COG-REAGENT: COGnitive tRaining in patiEnts With Amnestic Mild coGnitive impairmENT N/A
Terminated NCT01953601 - Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) Phase 3
Recruiting NCT06041152 - Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment Phase 2
Completed NCT01962038 - A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment N/A
Recruiting NCT03133052 - CTA-MCI: Cognitive Control Training in Patients With Amnestic Mild Cognitive Impairment(CTA-MCI) N/A
Not yet recruiting NCT05987007 - Sleep Interventions and Neurocognitive Outcomes N/A
Recruiting NCT04240561 - Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia N/A
Completed NCT01767909 - The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) Phase 2/Phase 3
Terminated NCT01072812 - Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment Phase 1
Completed NCT00643266 - Recollection Training in Healthy Older Adults and Older Adults With Amnestic Mild Cognitive Impairment N/A
Active, not recruiting NCT04504630 - Noninvasive Brain Stimulation on Memory in Individuals With Mild Cognitive Impairment and History of Brain Injury N/A
Terminated NCT00582855 - Effect of AQW051 in Patients With Memory Impairment Phase 2
Recruiting NCT05446584 - Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History Phase 2